Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 58 Colonic Neoplasms 24 Rectal Neoplasms 22 Neoplasms 19 Pancreatic Neoplasms 18 Neoplasm Metastasis 17 Esophageal Neoplasms 9 Stomach Neoplasms 8 Carcinoma, Non-Small-Cell Lung 7 Sarcoma 6 Small Cell Lung Carcinoma 5 Lung Neoplasms 5 Glioma 5 Glioblastoma 5 Brain Neoplasms 5 Neuroblastoma 4 Gliosarcoma 4 Esophageal Squamous Cell Carcinoma 4 Carcinoma, Renal Cell 4 Melanoma 3 Intestinal Neoplasms 3 Gastrointestinal Neoplasms 3 Breast Neoplasms 3 Adenocarcinoma Of Esophagus 3 Adenocarcinoma 3 Sarcoma, Ewing 2 Recurrence 2 Rectal Diseases 2 Ovarian Neoplasms 2 Oligodendroglioma 2

Interventions

iadademstat 1 Temozolomide 1 Sunitinib 1 Paclitaxel 1 PE regimen 1 Irinotecan 1 Fluorouracil 1 Everolimus 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma, Neuroendocrine × Irinotecan × Clear all

NCT03387592 2025-03-10

SENECA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡